Nalmefene and Naloxone for Fentanyl-Induced Respiratory Depression
A recent study published in The Journal of Clinical Pharmacology reveals that intramuscular nalmefene effectively reverses fentanyl-induced respiratory depression....
Jon Napitupulu
Early TAVR Superiority in Asymptomatic Severe Aortic Stenosis
The EARLY TAVR Trial, a groundbreaking study, evaluated the optimal approach to treating asymptomatic severe aortic stenosis (AS). It...
Organon Completes Acquisition of Dermavant
Organon, a global healthcare company focused on women’s health, has finalized its acquisition of Dermavant Sciences Ltd. from Roivant....
Boomi, Base Life Science Partner to Boost Digital Transformation
Boomi, a leader in intelligent integration and automation, has partnered with BASE Life Science, an Infosys company specializing in...
Aditxt Finalizes Evofem Merger Investment
Aditxt, Inc., a company focused on driving health innovations, has reached a significant milestone in acquiring Evofem Biosciences, Inc.,...
Leo Pharma Presents Long-Term Adbry® Trial Results at Fall Clinical 2024
LEO Pharma Inc., a leader in medical dermatology, announced the final results of ECZTEND, a five-year study on Adbry®...
Dermavant Unveils VTAMA Cream Data for Atopic Dermatitis
Dermavant Sciences has released promising data from their ADORING 3 study, highlighting the effectiveness of VTAMA cream, 1% in...
Engene Secures $60 Million in Private Placement Financing
enGene Holdings Inc., a clinical-stage genetic medicines company, has entered into an agreement to sell 6,758,311 of its common...
Odyssey Therapeutics Presents New Data on RIPK2 Inhibitor at ACG 2024
Odyssey Therapeutics, a clinical-stage biopharmaceutical company, is set to present promising data on its receptor-interacting protein kinase 2 (RIPK2)...
ABIONYX Presents Positive RACERS Study Results at ASN Kidney Week 2024
ABIONYX Pharma, a company focused on developing innovative therapies using recombinant human apoA-I, announced that its Phase 2b RACERS...